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Although ex vivo expanded T cells are currently widely used in pre-clinical and clinical trials, the complexity of manufacture
remainsamajorimpedimentforbroaderapplication.Inthisreviewwediscusscurrentprotocolsforthe exvivoexpansionofvirus-
and tumor-speciﬁc T cells and describe our experience in manufacture optimization using a gas-permeable static culture ﬂask (G-
Rex). This innovative device has revolutionized the manufacture process by allowing us to increase cell yields while decreasing the
frequency of cell manipulation and in vitro culture time. It is now being used in good manufacturing practice (GMP) facilities for
clinical cell production in our institution as well as many others in the US and worldwide.
1.Introduction—TCellTransfer
Cell therapy is a new but rapidly expanding ﬁeld in biotech-
nology which involves the administration of autologous or
allogeneic cells that carry out a therapeutic eﬀect in vivo.
The ﬁrst adoptive T cell transfer protocols in the allogeneic
hematopoietic stem cell transplant (HSCT) setting were
based on the premise that donor peripheral blood contained
T cells able to mediate antitumor and/or antiviral activity
in the HSCT recipient. Accordingly, donor lymphocyte
infusions (DLIs) have been extensively used to provide both
antitumor and antiviral immunity. However, the relatively
high frequency of alloreactive cells compared with virus-
and/ortumor-speciﬁcTcellsresultsinasigniﬁcantincidence
of graft-versus-host disease (GvHD), thereby limiting the
applicability of this approach. Infusion of enriched antigen-
speciﬁc T cells with reactivity against a particular antigen
potentially increases therapeutic potency while decreasing
undesired “oﬀ-target” eﬀects or GvHD, and this ﬁeld has
grown over the past two decades. This paper focuses on the
production of in vitro expanded antigen-speciﬁc T cells, dis-
cusses conventional and current technologies for T cell gen-
eration,andoutlinesrecentadvancesincellproductiontech-
niques which may ultimately move this therapeutic modality
from a boutique application towards a “standard of care.”
2. Infusion of Ex Vivo ExpandedCTL
The infusion of in vitro expanded donor-derived virus-
directed cytotoxic T lymphocytes (CTLs) targeting one
(Epstein-Barr virus (EBV)), two (EBV and Adenovirus
(Adv)), or three viruses (EBV, Adv, cytomegalovirus (CMV))
h a sp r o v e nt ob es a f e ,e ﬀective, and protective in vivo [1–
4]. The adoptive transfer of tumor antigen-directed T cells
has also induced objective tumor responses and complete
remissions in patients with advanced lymphoma, melanoma,
and nasopharyngeal carcinoma [5–10]. Recent advances in
molecular biology techniques have increased the enthusiasm
for this therapeutic modality by (1) allowing the genetic
modiﬁcation of T cells with a wide range of genes which
confer new antigen speciﬁcity by transferring T cell receptors
(TCRs) or chimeric antigen receptors (CARs) [11–14],
(2) improving the homing and proliferative properties of
eﬀector cells [15, 16], and (3) controlling unwanted T cell
proliferation or in vivo activity [12, 17–20].
Although the administration of in vitro expanded anti-
gen-speciﬁc CTLs has produced promising clinical results,
there are several factors limiting the extension of this
approach beyond the research arena. A major practical
constraint is the current complexity associated with produc-
tion of large number of cells using traditional manufacture2 Stem Cells International
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Figure 1: Increased frequency of antigen-speciﬁc CTLs after in
vitro stimulation. (a) illustrates the low frequency of antigen-
speciﬁc CTLs present in peripheral blood and the subsequent
enrichment after antigen stimulation. (b) shows the enrichment
of QAKWRLQTL- (HLA-B8-restricted EBV epitope-) speciﬁc T
cells in a seropositive donor as evaluated by tetramer analysis. (c)
illustrates the inverse correlation between the frequency of antigen-
speciﬁcandalloreactiveTcellsinperipheralblood(left)andinvitro
expanded CTLs (right).
protocols. However, some recent advancements streamlined
the production process.
3.Ex vivo Expansionof Antigen-SpeciﬁcT Cells
The ex vivo generation of antigen-speciﬁc T cells is conven-
tionally accomplished by repeat in vitro stimulation with
professional or artiﬁcial antigen presenting cells (APCs)
whichexpresstheproteinorpeptideofinterestandculturein
the presence of cytokines which promote T cell proliferation,
such as interleukin- (IL-) 2 [1, 21, 22]. This process results
in the ampliﬁcation and enrichment of T cells directed
againstthestimulatingantigen/peptidewithacorresponding
decrease in the frequency of cells with undesired speciﬁcities
such as alloreactive T cells (Figure 1). Once suﬃcient cells
(required for adoptive transfer) are generated, these are then
tested for potency, purity, identity, and sterility prior to
infusion.
For example, EBV-speciﬁc CTLs can be expanded ex
vivo from EBV-speciﬁc T cell precursors generally present
at a frequency of up to 1% in the peripheral blood of
most seropositive individuals. Traditionally, enriched T cell
lines are prepared by coculturing 1×106 peripheral blood
mononuclear cells (PBMCs) per cm2 with gamma-irradiated
(40Gy) autologous EBV-transformed lymphoblastoid cell
lines (EBV-LCLs) at a 40:1 ratio (PBMC:LCLs) in a total
volume/well(ofatissueculturetreated24-wellplate)of2mL
CTL growth media (RPMI 1640 supplemented with 45%
Click medium (Irvine Scientiﬁc, Santa Ana, Calif), 2mM
GlutaMAX-I,and10%FBS).Betweendays9and12CTLsare
harvested, counted, resuspended in fresh media, re-seeded at
5×106 per cm2 in a total volume of 2mL of CTL media, and
then fed with recombinant IL-2 (50U/mL) 4 days later. This
initial 13–16-day culture period in the absence of exogenous
cytokines gives a proliferative/survivaladvantage to the small
population of EBV-speciﬁc T cells present in PBMCs, which
both produce and use IL-2 in an autocrine manner upon
stimulation with EBV-LCL. However, at later time points,
when cultures are exclusively EBV speciﬁc the level of avail-
able cytokine becomes limiting and thus cultures must be
supplemented to ensure that CTL proliferation is adequately
supported [23]. Subsequent stimulations are performed
every 7 days using a 4:1 CTL:EBV-LCL ratio with twice
weekly addition of IL-2 (50U/mL). This ex vivo propagation
of EBV-speciﬁc T cells continues until suﬃcient cells are
generated for cryopreservation and quality control analysis
including HLA typing to conﬁrm identity, purity, and
safety testing. All products must meet the speciﬁed release
criteria before they are released for infusion. Additional
analysis on speciﬁc products such as assessment of transgene
expression may also be performed. For example, one of
the release criteria for chimeric-antigen-receptor- (CAR-)
modiﬁed EBV-CTLs is that at least 15% of cells must express
the transgene. Though there are diﬀerent CTL generation
protocols used by diﬀerent groups, even for the generation of
the “same” product, the component parts/core requirements
(antigen, APC, and cytokine) are essentially the same.
4. Traditionalin vitro Culture of
Antigen-SpeciﬁcTcells
A large variety of manufacturing protocols have been
described for the in vitro expansion of T cells. Small
numbers of suspension cells (<5×107)c a nb er e l a t i v e l y
easily propagated using conventional multiwell tissue culture
treated plates or ﬂasks. However, when the number of cells
required exceeds the maximum capacity of a single plate or
ﬂask (e.g., >5×107) this platform becomes time consuming
and cumbersome to manipulate.
Cell propagation in vitro is limited by requirements
for nutrients and oxygen (O2) and by the accumulation
of metabolic waste such as lactic acid and carbon dioxide
(CO2). Cell culture in conventional cultureware is restricted
to the use of speciﬁc media volumes per surface area unit,
that is, a maximum of 1mL media should be added per cm2
sincethisispermissivetogasdiﬀusion.However,thisshallowStem Cells International 3
media volume limits both the available nutrients and the
buﬀering capacity of the media. In addition, as cell num-
bers increase, O2 and nutrient requirements progressively
increase,sothatculturesmustbefedandre-seededregularly.
These frequent medium changes and cell manipulations are
time consuming and expensive, reduce the reproducibility of
cell production, and increase the risk of contamination.
5. AlternativeVesselsfor T Cell Expansion
One way to overcome the limitations associated with scale-
up using conventional cultureware is to instead utilize a
cell bioreactor that provides mechanical rocking or stirring
to perfuse media with gas. The use of such bioreactors
augments cell expansion, resulting in higher cell densities
beyond that attained using conventional plasticware.
A large number of bioreactors (hollow ﬁber bioreactors,
stirred tank bioreactors, and WAVE bioreactors) have been
explored for the expansion of suspension cells such as
activated T cells, genetically modiﬁed T cells, or antigen-
speciﬁcCTL[23–27].Inthesebioreactorsoxygenisprovided
bymechanicalrockingorstirringorbypumpinggasthrough
the culture while medium can be exchanged by perfusion.
Stirred bioreactors allow excellent gas exchange and can be
scaled up relatively easy. However, shear stress associated
with the stirring rate adversely aﬀects cell viability and thus
it has not been broadly adapted [28]. In contrast, hollow
ﬁber bioreactors allow a constant perfusion of the culture,
thus diluting metabolites without shear stress. However,
accessibility to this device makes it diﬃcult to eﬃciently
recover the expanded cells [24]. Static culture bags limit the
achieved cell densities (per input media volume). Thus, the
generation of large cell numbers requires the use of large
media volumes with a resultant increase in the frequency
of manipulations required to obtain the ﬁnal product [29].
Although the WAVE Bioreactor has been eﬀectively adapted
for the expansion of primary T cells, resulting in the
generation of large numbers of cells (1015), the culture bag
cannot be accommodated in a standard incubator and must
be heated and rocked in an expensive, custom-made device
[30, 31]. In addition, optimal cell growth is maintained
by regular measurement of oxygen and lactic acid and a
peristaltic pump is needed to move medium in and out of
the bag, necessitating the incorporation of special ﬁlters to
prevent cells being damaged by the pump. Further, gas is
propelled through the culture using a control ﬂow meter
which ensures that culture osmolarity is maintained.
Although antigen nonspeciﬁc T cell cultures have been
grown with some success in these various bioreactors,
antigen-speciﬁc T cells have strict requirements for cell-to-
cell contact and have proven diﬃcult to consistently adapt
to moving cultures. Therefore many groups, including our
own, have found it diﬃcult to improve upon results achieved
using the 2cm2 wells of standard tissue culture-treated 24-
well plates, which are ideal for the expansion of small
numbersofcellsrequiredforpreclinicalandproofofconcept
studies but limit the translation of antigen-speciﬁc T-cell-
basedtherapiesbeyondtheacademiclevel(Figure 2).Table 1
C
e
l
l
n
u
m
b
e
r
s Bioreactor
cultures
Cost/procedure complexity
static cultures
Multiwell plates, ﬂasks
Figure 2: Increased cost and procedure complexity with large-
scale cell requirements. As illustrated multiwell plates or ﬂasks
are ideal for the expansion of small numbers of antigen-speciﬁc
CTLs (<5×107). However, this system becomes ineﬀective for the
expansion of large numbers of cells. In contrast cell bioreactors are
ideal for the production of large cell numbers, but this platform is
diﬃcult to adapt and requires specialized equipment.
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Figure 3: Dynamic bioprocess optimization. This dynamic interac-
tion between the optimization and the preclinical phase allows for
easy transition of a cell product into the cGMP.
shows the relative advantages and disadvantages associated
with each of the culture vessels which have been used to
produce T cell products for clinical applications.
6.DynamicBioprocess Optimization
The problem with most manufacturing processes is the
misconception that a product can be produced on a large
scale by simply using a linear scale-up model. In most
cases this is simply not feasible given that the production
protocols are, for the most part, specialized, highly
complicated, and convoluted. One way to overcome this
scale-up problem, which is a bottleneck in conventional
cellular therapies, is to incorporate bioprocess optimization
in the manufacturing process. That will ultimately pave the
way for an easy transition into the GMP and will almost
guarantee manufacturing success, thus positively impacting
the outcome of a clinical study. This bioprocess optimization
(as illustrated in Figure 3) should not be considered4 Stem Cells International
Table 1: Suitability and properties of diﬀerent culture vessels for T cell expansion.
Cell culture
vessels Gas exchange Volume of media Cell concentration Disadvantages Advantages
Multiwell
plates/ﬂasks
(static cultures)
Limited
Limited: low ratio
of medium to
surface area
Low
High risk of contamination
Suitable for small-scale
cell production
Extensive processing time
Frequent interventions
Not scalable
Gas-permeable
bags (static
cultures)
Good
Limited: low ratio
of medium to
surface area
Medium
Low output per bag
requires constant culture
maintenance Sterility of closed
system
Limited microscopic cell
examination
Not linearly scalable from
research to production
G-Rex
(gas-permeable
static cultures)
Excellent
Unrestricted: high
ratio of medium to
surface area
High Limited microscopic cell
examination
Excellent O2 exchange
Linearly scalable from
research to large-scale
production
Signiﬁcantly reduced
culture manipulation
Compatible with
closed system
Wave action
bioreactors with
CO2/O2 aeration
& pH controllers
(dynamic
cultures)
Good
Unrestricted: high
medium capacity
in each bag
High
Complex, costly, requires
special equipment.
Excellent O2 exchange
yields large cell
numbers Not well suited to coculture
stage of CTL production
Requires constant culture
maintenance. Limited
microscopic cell
examination
Closed system
Not linearly scalable from
research to large-scale
production
a “validation stage” but instead a dynamic interaction
between the preclinical phase and manufacturing optimi-
zation that seeks to simplify the product generation, while
ensuring that the cell product maintains the biological
properties achieved in small scale manufacture.
7. Our Experience
One example of manufacture optimization that we have
undertaken over the past 4 years at the Center for Cell and
Gene Therapy (CAGT) at Baylor College of Medicine and
supported by Production Assistance for Cellular Therapies
(PACT) surrounds our search for simpler and more rapid
strategies to expand antigen-speciﬁc T cells for adoptive
transfer. Traditionally our group and others have cultured
virus- and tumor-directed T cells in 2cm2 wells of tissue
culture treated 24-well plates. These T cells are often
propagated for 8 weeks or longer to achieve the cell numbers
required for clinical application. However, the restricted
media ratio (1mL/cm2) associated with gas diﬀusion limits
the supply of nutrients, which are rapidly consumed by
proliferating T cells. Consequent acidic pH and waste build-
up rapidly impedes cell growth and survival. Therefore, the
onlyalternativeforcellpropagationisfrequentreseedingand
medium exchange which increases the frequency of manip-
ulation required with a concomitant increase in the risk of
contamination. Thus, we sought to optimize our antigen-
speciﬁc T cell culture process which led us to evaluate a novel
cell culture device (gas-permeable cultureware (G-Rex)),
developed by Wilson Wolf Manufacturing, and in which O2
and CO2 are exchanged across a silicone membrane at the
base of the ﬂask. Because gas exchange occurs from below
this allows an increased depth of medium above, which
provides more nutrients required by the cells while waste
products are diluted, thus not adversely aﬀecting cell growth
(Figure 4).
These optimal culture conditions provided by the G-
Rex result in improved cell viability and increased ﬁnal cell
numbers without increasing the number of cell doublings,
and decreasing the feeding frequency and the number of
manipulations required [32]. For example, for the expansion
of EBV-CTLs using the G-Rex we co-culture 1×106 PBMCs
per cm2 using a G-Rex10 (surface area of 10cm2—totalStem Cells International 5
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Figure 4: G-Rex culture device. (a) shows the limited gas exchange that occurs in conventional cultureware, which limits the volume of
media and consequently the available nutrients. In contrast the G-Rex provides gas exchange from the base of the ﬂask which allows cells to
be cultured with a superior ratio of media per surface area. (b) shows the G-Rex10 with a surface area of 10cm2 and a volume capacity of
40mLs, the G-Rex100 with a surface area of 100cm2 and a volume capacity of 500mLs, and the G-Rex1000 with a surface area of 1000cm2
and a volume capacity of 5000mLs.
of 1×107 PBMCs) with gamma-irradiated (40Gy) EBV-
LCLs at a 40:1 ratio in a ﬁnal volume of 40mL of CTL
medium. On days 9–12 the second stimulation is performed
by removing 20mL of media (aspirated from the top) and
adding 20mLs of fresh CTL medium containing irradiated
EBV-LCLs, resuspended at a cell density appropriate to
stimulate T cells at a ratio 4:1. Four days after the second
stimulation 50U/mL of IL-2 is added directly to the culture.
Oncethecellshaveexpandedtoadensityof>5×106 percm2
the cells are transferred to a G-Rex100 (surface area 100cm2)
and stimulated with irradiated EBV-LCL (4:1) in a ﬁnal
volume of 500mLs of media. These culture conditions have
allowed us to decrease the frequency of culture manipulation
while increasing the cell output (3–20-fold) and shortening
the time of culture [32]( Figure 5). We demonstrated that
this novel culture system supports the expansion of almost
any type of suspension cell, is GMP-compliant, and reduces
the number of technician interventions approximately 4-fold
[32].
Thismanufactureoptimizationhasbeenvalidated,trans-
ferred to our GMP facility in 2009 and is now used for all
of our CTL production processes. Since that time we have
allowed other centers, including the NCI, to cross-reference
our IND to enable the use of this cell culture technology in
other GMP facilities both within the US and beyond, and
this platform is currently used for production of numerous
cellular products including activated T cells, antigen-speciﬁc
CTLs, NK cells, regulatory T cells, and feeder cells including
EBV-LCLs and aK562 [32]. Importantly, cell culture in the
G-Rex can also be linearly scaled which allows an easy
transition of protocols from small to large scale. We recently
demonstrated this using the new G-Rex600 and G-Rex1000
(surface area of 600 and 1000cm2, resp.), which can generate
up to 6×109–1×1010 cells, respectively, in a single device.6 Stem Cells International
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Figure 5: Optimization of antigen-speciﬁc CTL manufacture decreases the number of interventions while increasing the cell output. (a)
illustrates the level of complexity associated with the generation of antigen-speciﬁc CTLs using conventional 24-well plates and the reduced
number of interventions required when reproducing the same protocol using the G-Rex. (b) shows how the implementation of the G-Rex
device decrease the in vitro culture time when compared with the conventional method.
8.Third-PartyCTLs
These manufacturing improvements have allowed us to
consider the use of virus-speciﬁc CTLs in the 3rd-party
setting and recently we have developed a cell bank to
facilitatethisendeavor.Administrationofthis“oﬀ-the-shelf”
productraisestwopotentialconcerns:(i)theriskofinducing
GvHD by administering a partially HLA-mismatched CTL
product and (ii) limited in vivo persistence, due to recipient
alloreactivity directed against nonshared HLA antigens.
Nevertheless a number of small studies have demonstrated
the feasibility of this approach in the patients with EBV
lymphoma arising after HSCT or solid organ transplant.
Haque and colleagues used 3rd-party EBV-speciﬁc CTLs to
treat PTLD after solid organ transplant or SCT and showed
an encouraging response rate of 64% and 52% at 5 weeks
and 6 months, respectively [33]. In this study the CTLs were
selected by low-resolution typing and screened for high-
level killing of donor EBV-LCLs and low-level killing of
patient PHA blasts. The level of HLA matching ranged from
2/6 to 5/6 antigens, and there was a statistically signiﬁcant
trend towards a better outcome with closer matching at 6
months.Importantly,nopatientdevelopedGVHDafterCTL
administration. In another report two cord recipients with
EBVlymphomareceivedcloselymatchedEBV-speciﬁcTcells
resulting in complete resolution of their lesions [34].
Currently we are evaluating the safety and potency
of using “oﬀ-the-shelf” trivirus CTL for the treatment
of CMV, adenovirus, or EBV infections in patients after
HSCT with active infection and that do not respond to
conventional therapy. Preliminary results in >35 recipients,
most of whom had received alternative donor transplants,
are encouraging, with minimal toxicity and >80% achieving
complete or partial responses. If this trend continues, we
will generate a larger CTL bank to cover as many racial
groups as possible and progress to a phase II clinical trial
where we can ask more speciﬁc questions regarding the
persistence and function of the CTL in vivo. Such a study is
dependent on the ability to produce large numbers of CTLs
that maintain their speciﬁcity and functional activity and are
not “exhausted” by excessive in vitro passaging, and this has
become possible only recently with the advent of optimized
culture protocols in the G-Rex cultureware that eﬀectively
supports CTL expansion.Stem Cells International 7
9.FutureProspects
Manufacture optimization arises from constant and critical
reﬂection on the diﬀerent processes involved in the gener-
ation of a cellular product. The G-Rex culture device is just
one example of manufactureoptimization taking place at the
CAGT. We have also recently simpliﬁed the process of virus-
speciﬁc CTL generation by replacing viral vectors and live
virus (previously used as antigen sources) with clinical grade
plasmids and overlapping peptide libraries [35]. We have
also discovered that certain combinations of enhancing and
stimulatory cytokines support the eﬃcient activation and
expansion of both virus- and tumor-reactive CTLs, leading
to the new GMP-compliant protocols that enable the rapid
generation of high-quality cellular products. Although the
manufacture optimization is a research phase that requires
t i m e ,m o n e y ,a n de ﬀort, this is an investment and a pre-
requisite for the manufacturing success of a cell product.
Ultimately, the ﬁnal “value” of a cell product depends on the
in vivo therapeutic eﬃcacy; however, it is the manufacture
process that either facilitates or restrains the evolution of
such products from the boutique to the mainstream.
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